Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OCRELIZUMAB Cause Progressive multiple sclerosis? 63 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 63 reports of Progressive multiple sclerosis have been filed in association with OCRELIZUMAB (OCREVUS). This represents 0.1% of all adverse event reports for OCRELIZUMAB.

63
Reports of Progressive multiple sclerosis with OCRELIZUMAB
0.1%
of all OCRELIZUMAB reports
1
Deaths
11
Hospitalizations

How Dangerous Is Progressive multiple sclerosis From OCRELIZUMAB?

Of the 63 reports, 1 (1.6%) resulted in death, 11 (17.5%) required hospitalization, and 4 (6.3%) were considered life-threatening.

Is Progressive multiple sclerosis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OCRELIZUMAB. However, 63 reports have been filed with the FAERS database.

What Other Side Effects Does OCRELIZUMAB Cause?

Covid-19 (11,454) Fatigue (5,704) Urinary tract infection (3,618) Headache (3,036) Multiple sclerosis (2,609) Asthenia (2,509) Nasopharyngitis (2,479) Gait disturbance (2,384) Pneumonia (2,333) Pain (2,327)

What Other Drugs Cause Progressive multiple sclerosis?

DIMETHYL (110) INTERFERON BETA-1A (105) NATALIZUMAB (99) DALFAMPRIDINE (89) GLATIRAMER (77) FINGOLIMOD (73) TERIFLUNOMIDE (48) OFATUMUMAB (26) OMEPRAZOLE (25) DULOXETINE (24)

Which OCRELIZUMAB Alternatives Have Lower Progressive multiple sclerosis Risk?

OCRELIZUMAB vs OCRIPLASMIN OCRELIZUMAB vs OCTINOXATE\OCTISALATE\ZINC OCRELIZUMAB vs OCTINOXATE\OCTOCRYLENE OCRELIZUMAB vs OCTREOTIDE OCRELIZUMAB vs OCTREOTIDE\OCTREOTIDE

Related Pages

OCRELIZUMAB Full Profile All Progressive multiple sclerosis Reports All Drugs Causing Progressive multiple sclerosis OCRELIZUMAB Demographics